Detalhe da pesquisa
1.
Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.
Am J Kidney Dis
; 81(2): 145-155.e1, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35843439
2.
Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children.
Genet Med
; 24(3): 654-662, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34906487
3.
The Nonclinical Disposition and Pharmacokinetic/Pharmacodynamic Properties of N-Acetylgalactosamine-Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human.
Drug Metab Dispos
; 50(6): 781-797, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34154993
4.
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.
Oncologist
; 23(8): 943-947, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29622697
5.
Pharmacokinetics and Pharmacodynamics of Patisiran in Patients with hATTR Amyloidosis and with Polyneuropathy After Liver Transplantation.
Clin Pharmacokinet
; 62(10): 1509-1522, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37639169
6.
Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1.
Kidney Int Rep
; 7(3): 494-506, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35257062
7.
Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria.
Clin Pharmacokinet
; 60(3): 365-378, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33047216
8.
Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects.
Clin Pharmacol Ther
; 109(2): 372-382, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32599652
9.
Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial.
Clin J Am Soc Nephrol
; 16(7): 1025-1036, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33985991
10.
Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria.
Clin Pharmacol Ther
; 108(1): 63-72, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31994716
11.
Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus.
J Clin Pharmacol
; 48(6): 696-707, 2008 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-18372428
12.
Cooperative binding of DNA and CBFbeta to the Runt domain of the CBFalpha studied via MD simulations.
Nucleic Acids Res
; 33(13): 4212-22, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-16049027
13.
Correction to: Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria.
Clin Pharmacokinet
; 61(6): 919, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35579826
14.
FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia.
Clin Cancer Res
; 21(16): 3586-90, 2015 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26275952
15.
FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma.
Clin Cancer Res
; 21(12): 2666-70, 2015 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25802282
16.
U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.
Clin Cancer Res
; 19(17): 4559-63, 2013 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23775332
17.
Population pharmacokinetic model for a novel oral hypoglycemic formed in vivo: comparing the use of active metabolite data alone versus using data of upstream and downstream metabolites.
J Clin Pharmacol
; 52(3): 404-15, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21422240
18.
Regulation of RUNX2 transcription factor-DNA interactions and cell proliferation by vitamin D3 (cholecalciferol) prohormone activity.
J Bone Miner Res
; 27(4): 913-25, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22189971
19.
U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.
Clin Cancer Res
; 18(21): 5845-9, 2012 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22962441
20.
Population pharmacokinetics of valsartan in pediatrics.
Drug Metab Pharmacokinet
; 24(2): 145-52, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19430170